Clinical Outcomes From NOCD Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention

• Sponsor: NOCD (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04701372
• Collaborator: (none)
• Enrollment: 2,069
• Location: 1
• Actual Duration (Months): 10.3
• Patients Per Site Per Month: 201.8

Study Details

Study Description

Brief Summary

This is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text messaging and an online community forum.

Condition or Disease	Intervention/Treatment	Phase
Obsessive-Compulsive Disorder	Behavioral: Exposure and response prevention therapy

Study Design

• Study Type: Observational
• Actual Enrollment: 2069 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: Clinical Outcomes From NOCD Digital Behavioral Health Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention
• Actual Study Start Date: Jan 1, 2020
• Actual Primary Completion Date: Nov 8, 2020
• Actual Study Completion Date: Nov 8, 2020

Arms and Interventions

Arm	Intervention/Treatment
Obsessive-Compulsive Disorder adults, adolescents, and children with obsessive-compulsive disorder	Behavioral: Exposure and response prevention therapy; Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.

Outcome Measures

Primary Outcome Measures

1. Dimensional Obsessive-Compulsive Scale [change from pre-treatment to post-treatment (after 11 weeks)]

   self-rated psychometric instrument to measure symptom severity of multiple OCD subtypes

Secondary Outcome Measures

1. Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND) OCD severity scale [pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)]

   clinician-rated psychometric instrument to measure overall OCD symptom severity

2. Depression Anxiety and Stress Scale (DASS-21) [pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)]

   self-rated psychometric instrument to measure depression, anxiety, and stress

3. Quality of Life Enjoyment and Satisfaction Questionnaire -- Short Form (QLES-Q) [pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)]

   self-rated psychometric instrument to measure quality of life

Eligibility Criteria

Criteria

• Ages Eligible for Study: 10 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• obsessive-compulsive disorder

Exclusion Criteria:

• none

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Nocd, Llc	Chicago	Illinois	United States	60601

Sponsors and Collaborators

• NOCD

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: NOCD
• ClinicalTrials.gov Identifier: NCT04701372
• Other Study ID Numbers: NOCD001
• First Posted: Jan 8, 2021
• Last Update Posted: Jan 8, 2021
• Last Verified: Jan 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by NOCD: exposure and response prevention; digital behavioral health; remote treatment; video therapy
• Additional relevant MeSH terms: Compulsive Personality Disorder; Obsessive-Compulsive Disorder

Study Results

No Results Posted as of Jan 8, 2021